Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion

MT Newswires Live

06/16

Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.

The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.

Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.

Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.

The company's shares rose 2% in recent Tuesday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2643738679"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643738679\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643738679?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 10:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643738679","market":"nz","top_or_hot":-1,"title":"Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion","media":"MT Newswires Live","content":"<html><body><p> Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.</p><p>The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.</p><p>Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.</p><p>Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 10:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.</p><p>The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.</p><p>Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.</p><p>Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NYR.AU","symbol_name":"NYRADA INC-CDI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643738679","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643738679","pubTimestamp":1781578431,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyrada  said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NYR.AU":"NYRADA INC-CDI","BK7096":"制药"},"translate_title":"Nyrada表示心脏病候选药物的2a期试验有望于2027年完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NYR.AU":1},"content_text":"Nyrada (ASX:NYR) said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}